Price Movement and Trading Activity
On 18 Feb 2026, Vivimed Labs Ltd witnessed a notable price rally, with the stock reaching its upper circuit limit of ₹7.46 from an opening low of ₹7.00. The last traded price (LTP) settled at ₹7.20, representing a 1.27% increase over the previous close. This price band movement of ₹0.35 was the maximum allowed for the day, triggering an automatic trading halt on further upward movement as per exchange regulations.
The total traded volume stood at 1.5044 lakh shares, with a turnover of ₹0.11 crore, indicating moderate liquidity for a micro-cap stock with a market capitalisation of ₹60.00 crore. Despite this, the stock outperformed its sector and benchmark indices, delivering a 0.84% return compared to the sector’s decline of 0.12% and the Sensex’s fall of 0.23% on the same day.
Strong Buying Pressure Amid Regulatory Freeze
The upper circuit hit is a clear sign of strong buying pressure, with demand outstripping supply at the prevailing price levels. However, the regulatory freeze on price movement means that while buyers remain eager, sellers have been unable or unwilling to offload shares beyond the circuit limit. This has resulted in unfilled demand, which could potentially fuel further gains once the price band restrictions are lifted.
Interestingly, the stock has been on a positive trajectory for the past two consecutive days, accumulating a 3.69% return during this period. This momentum is supported by the stock’s performance relative to its moving averages; it currently trades above its 5-day moving average but remains below the 20-day, 50-day, 100-day, and 200-day averages. This suggests a short-term bullish sentiment amid longer-term consolidation.
Declining Investor Participation Raises Caution
Despite the price gains, investor participation appears to be waning. Delivery volume on 17 Feb 2026 was recorded at 2 lakh shares, which is a sharp decline of 61.45% compared to the 5-day average delivery volume. This drop in delivery volume indicates that fewer investors are holding shares for the long term, potentially signalling profit-booking or cautious sentiment among market participants.
Liquidity remains adequate for small trade sizes, with the stock’s traded value representing approximately 2% of its 5-day average traded value. This level of liquidity supports trading activity but may limit large institutional participation given the micro-cap status of the company.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Fundamental and Market Context
Vivimed Labs Ltd operates within the Pharmaceuticals & Drugs industry, a sector that has experienced mixed performance amid evolving regulatory and market dynamics. The company’s micro-cap status, with a market cap of ₹60 crore, places it in a niche segment where volatility and liquidity constraints are common.
MarketsMOJO assigns Vivimed Labs a Mojo Score of 24.0, categorising it with a Strong Sell grade as of 05 Feb 2026, an upgrade from the previous Sell rating. This rating reflects concerns over the company’s fundamentals and market positioning despite recent price gains. The Market Cap Grade of 4 further underscores the challenges associated with its size and liquidity.
Investors should weigh the short-term price momentum against the broader fundamental outlook, which remains cautious. The stock’s recent outperformance relative to its sector by 2.8% is encouraging but must be contextualised within the company’s overall risk profile and valuation metrics.
Technical Indicators and Trading Outlook
From a technical perspective, the stock’s breach of the 5-day moving average signals a potential short-term uptrend. However, resistance levels at the 20-day and 50-day moving averages remain intact, suggesting that sustained gains will require stronger volume and positive catalysts.
The upper circuit hit acts as a double-edged sword; while it confirms strong demand, it also limits immediate price appreciation and may lead to volatility once the circuit restrictions are lifted. Traders should monitor volume trends closely, especially delivery volumes, to gauge genuine investor interest versus speculative activity.
Vivimed Labs Ltd or something better? Our SwitchER feature analyzes this micro-cap stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Investor Takeaway
Vivimed Labs Ltd’s upper circuit hit on 18 Feb 2026 highlights a surge in buying interest, driven by short-term optimism and technical momentum. However, the stock’s micro-cap nature, limited liquidity, and cautious fundamental ratings suggest that investors should exercise prudence.
Potential investors must consider the regulatory freeze on price movement, which may temporarily mask true market sentiment. The significant drop in delivery volumes also warrants attention, as it may indicate reduced conviction among long-term holders.
For traders, the current price action offers an opportunity to capitalise on momentum, but risk management is essential given the stock’s volatility and the possibility of sharp reversals once circuit limits are lifted.
In summary, while Vivimed Labs Ltd shows signs of short-term strength, a comprehensive evaluation of fundamentals, liquidity, and market conditions is crucial before making investment decisions.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
